Jessica Fye
Stock Analyst at JP Morgan
(4.08)
# 477
Out of 4,877 analysts
188
Total ratings
56.3%
Success rate
9.88%
Average return
Main Sectors:
Stocks Rated by Jessica Fye
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ONC BeOne Medicines | Maintains: Overweight | $317 → $321 | $242.34 | +32.46% | 2 | Jun 27, 2025 | |
| IONS Ionis Pharmaceuticals | Maintains: Neutral | $45 → $48 | $39.57 | +21.30% | 5 | Jun 12, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Overweight | $330 → $338 | $326.24 | +3.60% | 6 | Jun 12, 2025 | |
| MRNA Moderna | Maintains: Underweight | $33 → $26 | $27.62 | -5.87% | 13 | May 22, 2025 | |
| BNTX BioNTech SE | Maintains: Neutral | $120 → $116 | $106.67 | +8.75% | 11 | May 22, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $512 → $515 | $445.36 | +15.64% | 8 | May 6, 2025 | |
| BCRX BioCryst Pharmaceuticals | Maintains: Overweight | $10 → $13 | $9.00 | +44.52% | 6 | May 6, 2025 | |
| ASND Ascendis Pharma | Maintains: Overweight | $200 → $245 | $171.84 | +42.57% | 12 | May 2, 2025 | |
| UTHR United Therapeutics | Maintains: Overweight | $355 → $350 | $288.59 | +21.28% | 16 | May 1, 2025 | |
| INCY Incyte | Maintains: Neutral | $70 → $68 | $68.11 | -0.16% | 6 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $55 → $58 | $52.04 | +11.45% | 12 | Apr 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $54 → $50 | $31.26 | +59.95% | 5 | Apr 14, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $29 → $28 | $17.79 | +57.39% | 4 | Apr 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $200 → $209 | $106.20 | +96.80% | 4 | Feb 26, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $83 → $92 | $100.66 | -8.60% | 7 | Feb 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $28 → $24 | $14.00 | +71.43% | 5 | Jan 7, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $110 → $109 | $55.01 | +98.15% | 3 | Oct 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $32 → $26 | $28.64 | -9.22% | 6 | Oct 25, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $30 | $11.47 | +161.67% | 1 | Oct 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $47 → $54 | $28.73 | +87.96% | 5 | Jul 9, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $31 → $39 | $51.01 | -23.54% | 3 | Jun 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Neutral | $6 → $13 | $11.37 | +14.34% | 4 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $25.76 | - | 7 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $6.38 | - | 2 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Neutral | n/a | $1.00 | - | 9 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reinstates: Underweight | n/a | $16.25 | - | 6 | Nov 20, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $65 → $76 | $35.38 | +114.81% | 2 | Apr 19, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $1.71 | - | 2 | Aug 20, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $22 | $1.31 | +1,578.11% | 1 | Apr 19, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Neutral | $7 | $0.95 | +640.11% | 2 | Jan 29, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $32 → $27 | $29.71 | -9.12% | 5 | May 12, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $0.29 | - | 4 | Mar 11, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Underweight | n/a | $6.30 | - | 3 | Feb 28, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $7.51 | - | 1 | Feb 8, 2018 |
BeOne Medicines
Jun 27, 2025
Maintains: Overweight
Price Target: $317 → $321
Current: $242.34
Upside: +32.46%
Ionis Pharmaceuticals
Jun 12, 2025
Maintains: Neutral
Price Target: $45 → $48
Current: $39.57
Upside: +21.30%
Alnylam Pharmaceuticals
Jun 12, 2025
Maintains: Overweight
Price Target: $330 → $338
Current: $326.24
Upside: +3.60%
Moderna
May 22, 2025
Maintains: Underweight
Price Target: $33 → $26
Current: $27.62
Upside: -5.87%
BioNTech SE
May 22, 2025
Maintains: Neutral
Price Target: $120 → $116
Current: $106.67
Upside: +8.75%
Vertex Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $512 → $515
Current: $445.36
Upside: +15.64%
BioCryst Pharmaceuticals
May 6, 2025
Maintains: Overweight
Price Target: $10 → $13
Current: $9.00
Upside: +44.52%
Ascendis Pharma
May 2, 2025
Maintains: Overweight
Price Target: $200 → $245
Current: $171.84
Upside: +42.57%
United Therapeutics
May 1, 2025
Maintains: Overweight
Price Target: $355 → $350
Current: $288.59
Upside: +21.28%
Incyte
Apr 21, 2025
Maintains: Neutral
Price Target: $70 → $68
Current: $68.11
Upside: -0.16%
Apr 21, 2025
Maintains: Neutral
Price Target: $55 → $58
Current: $52.04
Upside: +11.45%
Apr 14, 2025
Maintains: Overweight
Price Target: $54 → $50
Current: $31.26
Upside: +59.95%
Apr 10, 2025
Maintains: Neutral
Price Target: $29 → $28
Current: $17.79
Upside: +57.39%
Feb 26, 2025
Maintains: Overweight
Price Target: $200 → $209
Current: $106.20
Upside: +96.80%
Feb 7, 2025
Maintains: Overweight
Price Target: $83 → $92
Current: $100.66
Upside: -8.60%
Jan 7, 2025
Maintains: Overweight
Price Target: $28 → $24
Current: $14.00
Upside: +71.43%
Oct 30, 2024
Maintains: Overweight
Price Target: $110 → $109
Current: $55.01
Upside: +98.15%
Oct 25, 2024
Maintains: Neutral
Price Target: $32 → $26
Current: $28.64
Upside: -9.22%
Oct 8, 2024
Initiates: Overweight
Price Target: $30
Current: $11.47
Upside: +161.67%
Jul 9, 2024
Maintains: Overweight
Price Target: $47 → $54
Current: $28.73
Upside: +87.96%
Jun 18, 2024
Maintains: Overweight
Price Target: $31 → $39
Current: $51.01
Upside: -23.54%
Mar 26, 2024
Maintains: Neutral
Price Target: $6 → $13
Current: $11.37
Upside: +14.34%
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $25.76
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $6.38
Upside: -
Nov 20, 2023
Reinstates: Neutral
Price Target: n/a
Current: $1.00
Upside: -
Nov 20, 2023
Reinstates: Underweight
Price Target: n/a
Current: $16.25
Upside: -
Apr 19, 2023
Maintains: Overweight
Price Target: $65 → $76
Current: $35.38
Upside: +114.81%
Aug 20, 2021
Downgrades: Underweight
Price Target: n/a
Current: $1.71
Upside: -
Apr 19, 2021
Initiates: Overweight
Price Target: $22
Current: $1.31
Upside: +1,578.11%
Jan 29, 2021
Upgrades: Neutral
Price Target: $7
Current: $0.95
Upside: +640.11%
May 12, 2020
Maintains: Overweight
Price Target: $32 → $27
Current: $29.71
Upside: -9.12%
Mar 11, 2019
Downgrades: Underweight
Price Target: n/a
Current: $0.29
Upside: -
Feb 28, 2019
Downgrades: Underweight
Price Target: n/a
Current: $6.30
Upside: -
Feb 8, 2018
Downgrades: Neutral
Price Target: n/a
Current: $7.51
Upside: -